Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatography assay for the novel antitumour agent CT2584 in human plasma

A HPLC assay and solid-phase extraction technique from human plasma has bee n developed and validated for the novel anticancer agent CT2584, 1-(11-dode cylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, which has recently comple ted a phase I trial at the Christie Hospital, Manchester under the auspices of the CRC phase I/II committee. Following addition of CT2576, 1-(11-octyl amino-10-hydroxylundecyl)-3,7-dimethylxanthine, as internal standard, a sol id-phase extraction cartridge (100 mg cyanopropyl) was used to isolate the drug CT2584 from human plasma. Analysis was performed by reversed-phase chr omatography. CT2576 was used as internal standard at a concentration of 4 m u g ml(-1) for the quantification of CT2584 from plasma for the duration of this work. The lower limit of quantification for the drug CT2584 in buffer using this assay was found to be 0.0122 mu M (0.008 mu g ml(-1)) and 0.048 mu M (0.027 mu g ml(-1)) when extracted from human plasma. (C) 1999 Elsevi er Science B.V. All rights reserved.